(1) PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. by Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PDP. Breast Cancer Res. 2010; 12(1): R1. Published online 2010 January 6. doi: 10.1186/bcr2464. PMCID: PMC2880419 [Full paper online]

(2) A population-based validation of the prognostic model PREDICT for early breast cancer. by Wishart GC, Bajdik CD, Azzato EM, Dicks E, Greenberg DC, Rashbass J, Caldas C, Pharoah PDP. Eur J Surg Oncol. 2011; 37(5): 411-7.

(3) PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. by Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, Greenberg DC, Green AR, Gelmon KA, Kosma VM, Olson JE, Beckmann MW, Winqvist R, Cross SS, Severi G, Huntsman D, Pylkas K, Ellis I, Nielsen TO, Giles G, Blomqvist C, Fasching PA, Couch FJ, Rakha E, Foulkes WD, Blows FM, Begin LR, Van't Veer LJ, Southey M, Nevanlinna H, Mannermaa A, Cox A, Cheang M, Baglietto L, Caldas C, Garcia-Closas M, Pharoah PD. Br. J. Cancer 2012;107(5):800-7.

(4) Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. by Wishart GC, Rakha E, Green A, et al. BMC Cancer.; 2014;14:908.

(5) Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer. by SK Down, O Lucas, JR Benson, GC Wishart. Oncol Lett.; 2014;8(6):2757-2761.

(6) An evaluation of the prognostic model PREDICT using the POSH cohort of women aged 40 years at breast cancer diagnosis. by Maishman T, Copson E, Stanton L, et al. Br J Cancer.; 2015 Mar 17;112(6):983-91.